MedTrace Logo

A Study Comparing the Safety and Effectiveness of Cartilage Cell Injected Into the Lumbar Disc as Compared to a Placebo

NCT01771471 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2017-08-31

No results posted yet for this study

Summary

This is a clinical study to collect safety and preliminary efficiency information on the use of NuQu chondrocytes (cartilage cells) delivered to the center of a lumbar spinal disc to treat low back pain.

Conditions

  • Degenerative Disc Disease

Interventions

BIOLOGICAL

NuQu

Allogenic juvenile chondrocytes (NuQu) in fibrin carrier.

OTHER

Placebo

0.9% w/v Sodium Chloride for Injection, USP

Sponsors & Collaborators

  • ISTO Technologies, Inc.

    lead INDUSTRY

Principal Investigators

  • Domagoj Coric, MD · Carolina Neurosurgery and Spine Associates

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01771471 on ClinicalTrials.gov